La Jolla Pharmaceutical (NASDAQ:LJPC)’s share price traded down 0% on Monday . The stock traded as low as $31.60 and last traded at $32.01. 1,440,000 shares traded hands during trading, an increase of 214% from the average session volume of 458,633 shares. The stock had previously closed at $32.01.

Several equities analysts have recently weighed in on the stock. BidaskClub upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating in a report on Friday. Jefferies Group lowered shares of La Jolla Pharmaceutical from a “buy” rating to an “underperform” rating and dropped their price objective for the company from $40.00 to $29.00 in a report on Monday. ValuEngine upgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a report on Wednesday, November 1st. Finally, Chardan Capital upped their price objective on shares of La Jolla Pharmaceutical from $90.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, January 25th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. La Jolla Pharmaceutical presently has an average rating of “Buy” and a consensus target price of $57.00.

The company has a market cap of $708.87, a PE ratio of -6.28 and a beta of 1.20.

In other news, Director Laura L. Douglass sold 10,000 shares of the business’s stock in a transaction dated Friday, December 29th. The shares were sold at an average price of $32.32, for a total transaction of $323,200.00. Following the completion of the sale, the director now directly owns 6,000 shares of the company’s stock, valued at $193,920. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Jennifer Carver bought 1,000 shares of the firm’s stock in a transaction dated Wednesday, December 27th. The shares were acquired at an average cost of $33.22 per share, with a total value of $33,220.00. Following the completion of the transaction, the chief operating officer now owns 4,500 shares of the company’s stock, valued at $149,490. The disclosure for this purchase can be found here. Insiders own 25.47% of the company’s stock.

Several large investors have recently bought and sold shares of LJPC. Janus Henderson Group PLC bought a new stake in shares of La Jolla Pharmaceutical during the second quarter worth about $25,191,000. State Street Corp increased its position in shares of La Jolla Pharmaceutical by 235.1% during the second quarter. State Street Corp now owns 1,180,368 shares of the biopharmaceutical company’s stock worth $35,140,000 after acquiring an additional 828,081 shares in the last quarter. Oak Ridge Investments LLC bought a new stake in shares of La Jolla Pharmaceutical during the third quarter worth about $14,642,000. Pictet Asset Management Ltd. bought a new stake in La Jolla Pharmaceutical in the 3rd quarter worth about $13,266,000. Finally, Candriam Luxembourg S.C.A. bought a new stake in La Jolla Pharmaceutical in the 3rd quarter worth about $6,295,000.

ILLEGAL ACTIVITY NOTICE: “La Jolla Pharmaceutical (LJPC) Shares Down 0%” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://theolympiareport.com/2018/02/12/la-jolla-pharmaceutical-ljpc-shares-down-0.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.